Israel Bio Fund Gp Limited ... Net Worth

The estimated Net Worth of Israel Bio Fund Gp Limited ... is at least $13.6 Million dollars as of 15 May 2024. Israel Limited owns over 24,344 units of BiomX Inc stock worth over $13,635,916 and over the last 2 years Israel sold PHGE stock worth over $9,251.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Israel Limited PHGE stock SEC Form 4 insiders trading

Israel has made over 2 trades of the BiomX Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Israel sold 24,344 units of PHGE stock worth $9,251 on 15 May 2024.

The largest trade Israel's ever made was buying 348,000 units of BiomX Inc stock on 27 February 2023 worth over $87,000. On average, Israel trades about 124,115 units every 148 days since 2023. As of 15 May 2024 Israel still owns at least 13,773,653 units of BiomX Inc stock.

You can see the complete history of Israel Limited stock trades at the bottom of the page.

Insiders trading at BiomX Inc

Over the last 5 years, insiders at BiomX Inc have traded over $332,366 worth of BiomX Inc stock and bought 1,036,414 units worth $787,614 . The most active insiders traders include James Edeerfield Management..., Chidozie Ugwumba, and Erez Chimovits. On average, BiomX Inc executives and independent directors trade stock every 68 days with the average trade being worth of $533,749. The most recent stock trade was executed by James Edeerfield Management... on 15 July 2024, trading 11,766,000 units of PHGE stock currently worth $11,648,340.

What does BiomX Inc do?

biomx is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (ibd) and cancer. we discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets. the company’s platforms use computational and synthetic biology and cutting-edge research from profs. rotem sorek, ph.d., eran elinav, m.d., ph.d., and eran segal, ph.d., of the weizmann institute of science; and professor timothy k. lu, m.d., ph.d., of the massachusetts institute of technology. investors in the company include orbimed israel incubator lp, johnson & johnson development corporation inc., takeda ventures, inc., seventure partners, mirae asset global investments, and sbi.

Complete history of Israel Limited stock trades at BiomX Inc

BiomX Inc executives and stock owners

BiomX Inc executives and other stock owners filed with the SEC include:

• Jonathan Solomon,
  Chief Executive Officer, Director
• Sailaja Puttagunta,
  Chief Medical Officer
• Assaf Oron,
  Chief Business Officer
• Dr. Merav Bassan Ph.D.,
  Chief Devel. Officer
• Russell Greig,
  Independent Chairman of the Board
• Lynne Sullivan,
  Independent Director
• Paul Sekhri,
  Independent Director
• Alan Moses,
  Independent Director
• Jonas Grossman,
  Independent Director
• Gbola Amusa,
  Independent Director
• Merav Bassan,
  Chief Development Officer
• Marina Wolfson,
  Principal Financial Officer, Vice President - Finance and Operations
• Dr. Regis A. Vilchez M.D., Ph.D.,
  Sr. VP & Head of Clinical Devel.
• Dr. Inbar Gahali-Sass,
  VP of Platform R&D
• Dr. Timothy K. Lu M.D., Ph.D.,
  Scientific Founder
• Dr. Eran Elinav M.D., Ph.D.,
  Scientific Founder
• Inbal Benjamini-Elran,
  VP of HR
• Noel Kurdi,
  VP of Investor Relations & Strategy
• Prof. Timothy K. Lu,
  Scientific Founder
• Dr. Eran Elinav,
  Scientific Founder
• Prof. Rotem Sorek Ph.D.,
  Scientific Founder
• Assaf Oron,
  Chief Bus. Officer
• Yaron Breski,
  Director
• Erez Chimovits,
  Director
• Thomas Layton Walton,
  10% owner
• Eddie Williams,
  Director
• Kerry Mountain Wood Llc Pro...,
  
• Israel Bio Fund Gp Limited ...,
  
• Chidozie Ugwumba,
  
• Susan Blum,
  Director
• Gregory Louis Merril,
  Director
• Jonathan S Leff,
  Director
• Jesse Goodman,
  Director
• James Edeerfield Management...,
  
• Israel Bio Fund Gp Limited ...,
  
• James Edeerfield Management...,
  
• Jason M. Marks,
  Director
• Michael E. Dambach,
  Director
• Fibrosis Foundation Cystic,